This study was for people who were currently suffering from post-COVID-19 condition (PCC) or can be called long COVID. Meaning since having a covid 19 infection, they still experience symptoms such as fatigue, shortness of breath, and cognitive dysfunction “brain fog” are example.

Purpose:  

To determine the impact of vortioxetine on the Cognitive deficits mood symptoms and significant reduction in health-related quality of life (HRQoL) in persons living with Post-Covid Condition (PCC).

​

Methods:

An 8-week randomized, double-blind, placebo-controlled study was conducted on adults ≥ 18 years of age residing in Canada and who are experiencing symptoms of World Health Organization (WHO)-defined Post-Covid Condition. Of the 200 participants enrolled, a total of 149 participants were randomized (1:1) to receive either vortioxetine (5–20 mg, n = 75) or placebo (n = 74) daily for 8 weeks of double-blind treatment (i.e. end point).

​

Results:

Anti-depressant effects and improvement in HRQOL Noted to be significantly more in the vortioxetine treated group. On the primary analysis, improvements were seen in cognition functions in people taking Vortioxetine However, the difference and improvement was not significantly greater than observed in the placebo arm overall. A subsequent secondary analysis of the data indicated that person with increased inflammatory marker i.e. CRP had a significantly greater improvement With vortioxetine in cognitive function suggesting the inflammatory system is affecting cognitive function in people with PCC.​​

​​

See more here:

Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial - PubMed (nih.gov)​

​

More of our studies on post-COVID-19 condition